BIORESTORATIVE THERAPIES INC. - COMMON STOCK

BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment

16 Apr 2024 07:45:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease

08 Apr 2024 07:45:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants

03 Apr 2024 16:38:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K

01 Apr 2024 07:45:00 By Nasdaq GlobeNewswire

BioRestorative Therapies to Participate in the 36th Annual ROTH Conference

11 Mar 2024 16:15:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market

06 Feb 2024 08:05:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease

05 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting

01 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity Program

12 Dec 2023 09:15:00 By Nasdaq GlobeNewswire

BioRestorative Therapies, Inc. to Participate at the ROTH MKM Healthcare Opportunities Conference October 12, 2023 in New York City

09 Oct 2023 12:10:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Enters into Supply Agreement with Evolutionary Biologics

12 Sep 2023 09:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease

08 Sep 2023 08:30:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Announces $2.1 Million Registered Direct Offering

11 Jul 2023 08:30:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Receives Unanimous Recommendation from Data Safety Monitoring Board (DSMB) to Continue its Phase 2 Clinical Trial without any Changes

27 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies, Inc. to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET

16 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Announces Key Milestone of Dosing Completion in Safety Cohort of Phase 2 Trial Targeting Chronic Lumbar Disc Disease

12 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies, Inc. to attend the Jefferies 2023 Healthcare Conference

01 Jun 2023 09:15:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Receives License from New York State Department of Health to act as Tissue Bank for Mesenchymal Stem Cell Processing

31 May 2023 07:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Receives Notice of Allowance by the Japanese Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program

15 May 2023 07:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies and Northwell Health Enter into Agreement to Participate in the Company’s Phase 2 Clinical Trial

08 May 2023 07:00:00 By Nasdaq GlobeNewswire